Biotechnology - Biotechnology, Inflammatory diseases


Popular Filters

1 to 25 of 31 results

Merck KGaA's Allergopharma to collaborate with S-TARget on new generation of allergy products

Merck KGaA's Allergopharma to collaborate with S-TARget on new generation of allergy products


Allergopharma, a division of Germany’s Merck KGaA, and Austrian allergy biotechnology company S-TARget…

AllergopharmaAustriaBiotechnologyGermanyImmunologyInflammatory diseasesMerck KGaAResearch

J&J affiliate Cilag GmbH International acquires Covagen

J&J affiliate Cilag GmbH International acquires Covagen


Cilag GmbH International, an affiliate of US health care giant Johnson & Johnson’s Janssen companies,…

Anti-Arthritics/RheumaticsBiotechnologyCilag GmbH InternationalCovagenFynomAbInflammatory diseasesJanssenJohnson & JohnsonMergers & Acquisitions

Celltrion files for US FDA approval of Remsima biosimilar

Celltrion files for US FDA approval of Remsima biosimilar


South Korean biopharmaceutical firm Celltrion says it has completed the filing procedure to obtain US…

BiosimilarsBiotechnologyCellTrionClinical researchInflammatory diseasesinfliximabJanssen BiotechJohnson & JohnsonPatentsRegulationRemicadeRemsimaUSA

Galapagos plunges as GSK gives up rights to developmental drug


Along with presenting first-half 2014 financial results today, Belgian biotech group Galapagos said its…

BiotechnologyFinancialGalapagosGlaxoSmithKlineGSK2586184Inflammatory diseasesLicensing

NicOx to acquire Aciex Therapeutics


Ophthalmology-focused French biotech firm NicOx has entered into an agreement to acquire all of the outstanding…

Aciex TherapeuticsBiotechnologyInflammatory diseasesMergers & AcquisitionsNicOxOphthalmics

High level of innovation seen in psoriasis treatment pipeline

High level of innovation seen in psoriasis treatment pipeline


Despite mostly targeting established molecules, the psoriasis pipeline is showing a high level of innovation…

BiotechnologyBiotest AGDermatologicalsInflammatory diseasesResearchtregalizumab

Amgen and AstraZeneca’s brodalumab meets all endpoints in Ph III study

Amgen and AstraZeneca’s brodalumab meets all endpoints in Ph III study


Anglo-Swedish drug major AstraZeneca and the USA’s Amgen have announced that the Phase III AMAGINE-1…

AmgenAstraZenecaBiotechnologybrodalumabInflammatory diseasesResearch

Lupin inks strategic biosimilars joint venture agreement with Yoshindo


Indian drugmaker Lupin has entered into a strategic joint venture agreement with Japanese pharma company,…

BiosimilarsBiotechnologyEnbrelInflammatory diseasesJapanLicensingLupinTakeda PharmaceuticalYoshindo

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech


Caisson Biotech, a wholly-owned subsidiary of Heparinex and owner of a patented heparosan-based drug…

BiotechnologyCaisson BiotechDiabetesInflammatory diseasesLicensingMetabolicsNovo Nordisk

Abide Therapeutics in deal with Celgene on immune disorders research


Privately-held Abide Therapeutics has entered into a strategic collaboration with US biotech firm Celgene…

AB101131Abide TherapeuticsBiotechnologyCelgeneImmunologicalsInflammatory diseasesLicensingMergers & Acquisitions

Vectura and UCB to collaborate on severe inflammatory disease

Vectura and UCB to collaborate on severe inflammatory disease


Vectura and UCB have entered into a collaboration for the development of an innovative biologic immuno-modulatory…

BiotechnologyEuropeInflammatory diseasesPharmaceuticalResearchRespiratory and PulmonaryUCBVectura

Novartis enters into a collaboration for Il-17 inhibitor


US biotech firm Ensemble Therapeutics, a company developing Ensemblins, a novel class of small molecule…

BiotechnologyEnsemble TherapeuticsImmunologicalsInflammatory diseasesLicensingNovartisPharmaceutical

Teijin and Amgen join forces on autoimmune disease research


Japan's Teijin Pharma, the core company of the Teijin Group's (TSE: 3401) health care business, has entered…

AmgenBiotechnologyImmunologicalsInflammatory diseasesLicensingPharmaceuticalResearchTeijin

Array BioPharma signs up to $387 million deal


In a second licensing deal this week US biotech major Celgene (Nasdaq: CELG) has entered into a strategic…

Array BioPharmaBiotechnologyCelgeneInflammatory diseasesLicensing

In Japan, Mitsubishi Tanabe files for canagliflozin approval; Eisai/AbbVie's Humira gets new indication


Japanese drug major Mitsubishi Tanabe Pharma (TYO: 4508) said yesterday (May 27) that it has submitted…

AbbVieAsia-PacificBiotechnologycanagliflozinDiabetesEisaiHumiraInflammatory diseasesInvokanaMitsubishi TanabePharmaceuticalRegulation

US FDA approves Janssen's Simponi to treat ulcerative colitis


The US Food and Drug Administration late yesterday (May 15) approved a new use for Johnson & Johnson…

BiotechnologyGastro-intestinalsInflammatory diseasesJanssen BiotechJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSimponi Injection

Concert Pharma in $300 million-plus deal with Celgene


Privately-held biotech firm Concert Pharmaceuticals said yesterday (May 6) that it has entered into a…

Anti-Arthritics/RheumaticsapremilastBiotechnologyCelgeneConcert PharmaceuticalsInflammatory diseasesLicensingOncologyResearch

Merck Serono spins out sixth company - Calypso Biotech - to focus on gastrointestinal immunological disorders


German drug major Merck KGaA's (MRK: DE) subsidiary Merck Serono yesterday (March 4) announced the creation…

BiotechnologyCalypso BiotechGastro-intestinalsInflammatory diseasesMerck KGaAMerck SeronoMergers & Acquisitions

FDA approves SOBI's Kineret for the treatment of NOMID


Biotech firm Swedish Orphan Biovitrum (STO: SOBI) today announced that the US Food and Drug Administration…

AmgenBiotechnologyInflammatory diseasesKineretNorth AmericaRegulationSobiSwedish Orphan Biovitrum

Licensing deals for Philogen with Pfizer and GlycoVaxyn with Janssen


Privately held Italian biopharma firm Philogen SpA (Siena, Italy) has granted global drugs behemoth Pfizer…

BiotechnologyDekavilGlycoVaxynInflammatory diseasesJanssenJohnson & JohnsonLicensingPfizerPharmaceuticalPhilogenVaccines

Phenex in up to $135 million research collaboration with Janssen


Privately-held German drug discovery firm Phenex Pharmaceuticals has entered into an agreement with Janssen…

Anti-Arthritics/RheumaticsBiotechnologyGastro-intestinalsInflammatory diseasesJanssenJohnson & JohnsonLicensingPhenex PharmaceuticalsResearch

European therapeutic MAbs market to reach over $42 billion in 2018, says F&S


Efficient resource to therapy of complex disorders with lesser side effects has accelerated growth of…

BiotechnologyImmunologicalsInflammatory diseasesMarkets & MarketingOncologyPharmaceuticalResearch

Theravance in up to $63.5 million deal with Alfa Wassermann for velusetrag; RuiYi links with arGEN-X on MAb


USA-based Theravance (Nasdaq: THRX) and Italy headquartered Alfa Wassermann have entered into an exclusive…

Alfa WassermannarGEN-XARGX-109BiotechnologyGastro-intestinalsInflammatory diseasesLicensingOncologyPharmaceuticalRuiYiTheravancevelusetrag

1 to 25 of 31 results

Back to top